These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 33728245)

  • 1. Diurnal variability of glucose tetrasaccharide (Glc
    Young SP; Khan A; Stefanescu E; Seifts AM; Hijazi G; Austin S; Kishnani PS
    JIMD Rep; 2021 Mar; 58(1):37-43. PubMed ID: 33728245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glucose tetrasaccharide as a biomarker for monitoring the therapeutic response to enzyme replacement therapy for Pompe disease.
    An Y; Young SP; Kishnani PS; Millington DS; Amalfitano A; Corz D; Chen YT
    Mol Genet Metab; 2005 Aug; 85(4):247-54. PubMed ID: 15886040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term monitoring of patients with infantile-onset Pompe disease on enzyme replacement therapy using a urinary glucose tetrasaccharide biomarker.
    Young SP; Zhang H; Corzo D; Thurberg BL; Bali D; Kishnani PS; Millington DS
    Genet Med; 2009 Jul; 11(7):536-41. PubMed ID: 19521244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Urinary excretion of a glucose-containing tetrasaccharide. A parameter for increased degradation of glycogen.
    Kumlien J; Chester MA; Lindberg BS; Pizzo P; Zopf D; Lundblad A
    Clin Chim Acta; 1988 Aug; 176(1):39-48. PubMed ID: 3168292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Urinary Glucose Tetrasaccharide Concentrations in Patients with Infantile- and Late-Onset Pompe Disease Identified by Newborn Screening.
    Chien YH; Goldstein JL; Hwu WL; Smith PB; Lee NC; Chiang SC; Tolun AA; Zhang H; Vaisnins AE; Millington DS; Kishnani PS; Young SP
    JIMD Rep; 2015; 19():67-73. PubMed ID: 25681082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urine glucose tetrasaccharide: A good biomarker for glycogenoses type II and III? A study of the French cohort.
    Piraud M; Pettazzoni M; de Antonio M; Vianey-Saban C; Froissart R; Chabrol B; Young S; Laforêt P;
    Mol Genet Metab Rep; 2020 Jun; 23():100583. PubMed ID: 32382504
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of liver GSD IX γ2 pathophysiology in a novel Phkg2
    Gibson RA; Lim JA; Choi SJ; Flores L; Clinton L; Bali D; Young S; Asokan A; Sun B; Kishnani PS
    Mol Genet Metab; 2021 Jul; 133(3):269-276. PubMed ID: 34083142
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid ultraperformance liquid chromatography-tandem mass spectrometry assay for a characteristic glycogen-derived tetrasaccharide in Pompe disease and other glycogen storage diseases.
    Sluiter W; van den Bosch JC; Goudriaan DA; van Gelder CM; de Vries JM; Huijmans JG; Reuser AJ; van der Ploeg AT; Ruijter GJ
    Clin Chem; 2012 Jul; 58(7):1139-47. PubMed ID: 22623745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective longitudinal study and comprehensive review of adult patients with glycogen storage disease type III.
    Hijazi G; Paschall A; Young SP; Smith B; Case LE; Boggs T; Amarasekara S; Austin SL; Pendyal S; El-Gharbawy A; Deak KL; Muir AJ; Kishnani PS
    Mol Genet Metab Rep; 2021 Dec; 29():100821. PubMed ID: 34820282
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hematopoietic stem cell transplantation in glycogen storage disease type Ib: A single-subject research design using
    Turki A; Stockler S; Sirrs S; Duddy K; Ho G; Elango R
    Mol Genet Metab Rep; 2023 Mar; 34():100955. PubMed ID: 36632325
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrosis during clinical ascertainment of glycogen storage disease type III: a need for improved and systematic monitoring.
    Halaby CA; Young SP; Austin S; Stefanescu E; Bali D; Clinton LK; Smith B; Pendyal S; Upadia J; Schooler GR; Mavis AM; Kishnani PS
    Genet Med; 2019 Dec; 21(12):2686-2694. PubMed ID: 31263214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a rapid simultaneous assay of two urinary tetrasaccharide metabolites using differential ion mobility and tandem mass spectrometry and its application to patients with glycogen storage disease (type Ib and II).
    Ren J; Ma Y; Ma M; Ding J; Jiang J; Zheng X; Han X
    Anal Bioanal Chem; 2023 Nov; 415(27):6863-6871. PubMed ID: 37770665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of a kit for urine collection on filter paper as an alternative for Pompe disease screening and monitoring by LC-HRMS.
    de Souza HMR; Scalco FB; Garrett R; de C Marques FF
    Anal Methods; 2023 Aug; 15(32):3932-3939. PubMed ID: 37539791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The decision-making levels of urine tetrasaccharide for the diagnosis of Pompe disease in the Turkish population.
    Canbay E; Vural M; Kalkan Uçar S; Sezer ED; Karasoy H; Yüceyar AN; Çoker M; Sözmen EY
    J Pediatr Endocrinol Metab; 2020 Mar; 33(3):391-395. PubMed ID: 32069240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of a glucose-containing tetrasaccharide in urine of patients with acute pancreatitis.
    Kumlien J; Andrén-Sandberg A; Zopf D; Lundblad A
    Int J Pancreatol; 1989 Mar; 4(2):139-47. PubMed ID: 2470839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of a glucose tetrasaccharide elevated in Pompe disease by stable isotope dilution-electrospray ionization tandem mass spectrometry.
    Young SP; Stevens RD; An Y; Chen YT; Millington DS
    Anal Biochem; 2003 May; 316(2):175-80. PubMed ID: 12711338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approach to prepare fluorogenic branched dextrins for assaying glycogen debranching enzyme.
    Sakaguchi M; Makino Y; Matsubara H
    Glycoconj J; 2020 Dec; 37(6):667-679. PubMed ID: 33201379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of minimally invasive
    Turki A; Stockler S; Sirrs S; Salvarinova R; Ho G; Branov J; Rosen-Heath A; Bosdet T; Elango R
    Mol Genet Metab Rep; 2022 Jun; 31():100880. PubMed ID: 35585965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of continuous glucose therapy begun in infancy on the long-term clinical course of patients with type I glycogen storage disease.
    Wolfsdorf JI; Crigler JF
    J Pediatr Gastroenterol Nutr; 1999 Aug; 29(2):136-43. PubMed ID: 10435649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel starch for the treatment of glycogen storage diseases.
    Bhattacharya K; Orton RC; Qi X; Mundy H; Morley DW; Champion MP; Eaton S; Tester RF; Lee PJ
    J Inherit Metab Dis; 2007 Jun; 30(3):350-7. PubMed ID: 17514432
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.